Physician profile
Cameron Meade
NPI 1912776782
$570.39
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.26 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.38 | 2024 | Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $118.53 | 2024 | Dupixent |
| Genentech USA, INC. | $26.00 | 2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2024 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $19.95 | 2024 | |
| Genzyme Corporation | $18.93 | 2024 | |
| Amgen INC. | $17.20 | 2024 | Tezspire |
| Pharming Healthcare, INC. | $15.96 | 2024 | Ruconest |
| Csl Behring | $15.91 | 2024 | Hizentra |
| Glaxosmithkline, LLC. | $15.37 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.